Abstract
Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, where it represents the third cause of cancerrelated death
. Because of differences in risk factors, regional incidence is widely variable. It ranges from 5.5 to 14.9 per 100,000 individuals, but it may reach 100 per 100,000 in some regions of [40] [41] [42] [43] . As it will be described below, one of the major mechanisms involved in the down-regulation of p27 and p57 is now believed to be the overexpression of the microRNAs (miRNAs) miR-221/222, which occurs in about 70% of HCCs [44] [45] [46] . On the contrary, some HCCs exhibit high cell proliferation in spite of high p27 expression. In these cases, p27 is thought to be inactivated by sequestration into cyclinD1-CDK4-containing complexes [47] .
Africa and South East Asia. Hepatitis B virus (HBV) infection is the main risk factor in Asia and Africa, whereas Hepatitis C virus (HCV) infection is the main risk factor in western countries and in
Thus, the identification of new possible targets for the development of non-conventional treatments is urgent and will necessarily take advantage of progresses in the comprehension of the molecular pathogenesis of HCC [5].
Molecular pathways and biological functions altered in hepatocarcinogenesis HCC results from the deregulation of multiple intracellular and extracellular signalling pathways. Initial steps involve the disruption of a set of interdependent pathways controlling the homeostasis between cell growth and apoptosis. At later stages, cells may acquire angiogenic, invasive and metastatic properties, in a process that involves the interactions of neoplastic cells with the surrounding microenvironment. To develop the above cancer traits, several elements of the Retinoblastoma (RB), p53, rat sarcoma virus oncogene (RAS), wingless-type (WNT) and transforming growth factor (TGF)-␤ pathways have been frequently found to be genetically or epigenetically altered in HCC.
Abnormal cell cycle control is not only a critical step in HCC maintenance, but it also appears to be a critical early event. Indeed, an increased proliferation rate and proliferating cell fraction characterize liver cirrhosis too, and correlate with a higher propensity to develop HCC.
The contribution of anti-apoptotic factors to hepatocarcinogenesis has been extensively studied [48] [49] [50] [53] ; furthermore, its overexpression could independently predict a decreased overall-and disease-free survival [54, 55] . Among the pro-apoptotic members of the Bcl-2 family, a down-regulation of the pro-apoptotic genes bax and bcl-Xs was observed in 80% and 64%, respectively, of HCCs [56, 57] . Similarly, the pro-apoptotic Bid was also found down-regulated in all HCCs from HBV-infected patients, and its down-regulation was related to HBV-X protein action [56] .
At [59] . [60, 61] 
Advanced tumour features include the ability of cancer cells to promote uncontrolled angiogenesis and invade tissues and blood vessels. In this regard, HCC is one of the most vascular solid tumours with high propensity for vascular invasion. The abovementioned aberrant signalling pathways are functional to this feature. Angiogenesis plays a crucial role in HCC development, growth and metastasis and is used as a diagnostic criterion. The switch to an angiogenic phenotype is triggered by the activation of genes like RAS, inactivation of p53, or cellular stress factors like hypoxia, reactive oxygen species and nutrient deprivation. Signalling pathways crucial for the angiogenic process include growth-factor-mediated pathways such as VEGF and FGF receptor signalling as well as the nitric oxide signalling. VEGF expression is stimulated by hypoxia through the hypoxia inducible factor-1 (HIF-1) and the IGF-2 and it is produced by both endothelial and tumour cells. VEGF exerts a mitogenic effect on endothelial cells and increases vascular permeability. The role of VEGF in the development of neovascularization of HCC has been extensively reported in the transition between low-grade dysplastic nodules to highgrade dysplastic nodules to early HCC. Furthermore VEGF expression correlates with HCC progression, metastatization, tendency towards portal invasion and higher recurrence rate. In addition to angiogenesis, another distinguished feature of HCC is its propensity towards vascular and tissue invasion. One of the signalling pathways conferring invasive potential to HCC cells, is mediated by the HGF/MET axis. HGF is the most potent growth factor for hepatocytes and, by binding to its transmembrane tyrosine kinase receptor, MET, it promotes proliferation and regeneration, migration, survival and angiogenesis and it is involved in the control of invasive growth both during tumourigenesis and in embryonic development
Numerous miRNAs are aberrantly expressed in human HCC
In the recent years, several studies revealed that the expression of miRNAs is deregulated in human HCC in comparison with matched non-neoplastic tissue [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . The list of aberrantly expressed miRNAs in HCC identified in various studies is reported in Table 2 . Among these, some miRNAs were identified as aberrantly expressed by more than one study ( [73] .
Biological and molecular functions affected by miRNA deregulated in HCC
The role of miRNAs either as oncogenes or tumour suppressors in human cancer has been established [83, 84] . Various studies have also begun to elucidate the molecular functional links between miRNA abnormal expression and the hallmarks of malignant transformation: aberrant cell growth, cell death, differentiation, angiogenesis, invasion and metastasis [85] . Here, we summarize the available evidence in HCC. [86, 87] (Fig. 1) . Genes for both miRNAs are methylated in HCCs. Table 3 [78] (Fig. 1) . Since let-7 is generally down-regulated in several human cancers, this mechanism could lead to the activation of the RAS pathway. As previously mentioned, it is interesting to note that a frequent overexpression but not point mutations of RAS has been reported in HCC.
As previously indicated, MET, the tyrosine kinase HGF receptor, is overexpressed in 40 to 70% of HCCs and is involved in cell motility, invasion and metastasis. Recent reports indicated that MET is post-trascriptionally regulated by miR-199a/a* and miR-1
Members of the miR-199 family emerged in several studies as frequently down-regulated in HCC (see
Let-7 has also been shown to repress the high-mobility group AT-hook 2 (HMGA2) oncogene [79, 80] [79] . [88] and repressed by p53 [89] , emerged as a significantly up-regulated miRNA in glioblastoma, pancreatic, hepatocellular, kidney, bladder, prostate and thyroid cancer [44-46, 73, 79, 90-94] [46, 93] . More recently, another cyclin-dependent kinase inhibitor, CDKN1C/p57, was also shown to be target of miR-221 [44, 45] , strengthening the role of miR-221 in promoting cell cycle progression (Fig. 1) [95, 96] [120, 121] . Reduced CDKN1C/p57 labelling index was associated with worse outcomes and lower disease-free survival after surgery, suggesting that CDKN1C/p57 down-regulation might contribute to the progression of HCC through modulation of cell growth [39, 122] . Overexpression of the anti-apoptotic gene bcl-xL [53] independently predicts a decreased overall-and disease-free survival [54, 55] . High throughput technologies have made possible to explore gene expression patterns on large series and to characterise molecular signatures associated with different aetiologies [123] [124] [125] , stage [126, 127] , propensity to recurrence [128] [129] [130] and prognosis [131, 132] (Gramantieri and Negrini, unpublished) . This is not unexpected, giving the fact that miR-221 regulates the expression of p27 and p57 [44] , two tumour suppressor proteins whose down-regulation was associated with poor prognostic factors in HCC [39, [120] [121] [122] . Recently, up-regulation of miR-210, one of the miRNA that is induced under hypoxia [133] , was associated with reduced disease-free and overall survival in breast cancer [134] . Since miR-210 is also up-regulated in HCC [97] as well as in a variety of solid cancers [135] [136] [137] [138] [139] . The use of imatinib mesylate, a platelet-derived growth factor receptor (PDGFR) and other tyrosine kinases inhibitor, has been suggested [140] [141] [142] ; however, in spite of initial positive results [143] , phase 2 clinical trials did not reveal any significant efficacy [144, 145] . [149, 150] . Both of these studies demonstrated a survival benefit using siRNA approach without significant side effects. These studies also confirmed a high hepatic uptake of siRNA following their systemic administration. Although several studies have established the potential usefulness of miRNA-based therapy in cancer [76, 81, 151, 152] [153, 154] . MiR-21 is overexpressed in colangiocarcinoma and its inhibition by AMOs increases sensitivity to the chemotherapeutic agent gemcitabine [155] . Either cholesterol-bound oligonucleotides (antagomirs), or LNA-modified oligonucleotides (LNA anti-miR) were also found to be effective in stably suppressing miRNA activity in the in vivo condition [156, 157] 
The disrupted repression of HMGA2 promotes anchorage-independent growth and the growth-suppressive effect of let-7 on lung cancer cells was rescued by overexpression of the HMGA2 ORF without a 3ЈUTR [79]. The link between the downregulation of let-7 and the simultaneous up-regulation of HMGA2 was functionally associated with a cancer stem cell signature, at least in the breast cancer cells SKBR3, by Yu et al. [82]. These important findings need to be assessed in HCC too. The importance of let-7 down-regulation in cancer is further supported by studies by Takamizawa et al. and Akao et al. [76, 81], who showed that let-7 can suppress the growth of A549 lung cancer cells and DLD-1 colon cancer cells in vitro. A direct role of miRNAs in controlling cell growth by acting on elements of the cell cycle machinery was provided by studies on miR-221. MiR-221, which was recently shown to be induced by MYCN
, thus suggesting an oncogenic role in several human neoplasms. Its oncogenic function was substantiated by the discovery of its ability to modulate the expression of the cyclindependent kinase inhibitor CDKN1B/p27, a key controller of cell cycle progression
. Moreover, the BH3-only protein BMF was recently proven to be a target of miR-221 (Gramantieri and Negrini, manuscript in preparation). Through this mechanism, miR-221 could protect cells from 'anoikis', a form of Apoptosis induced by the detachment of anchorage-dependent cells from the surrounding extracellular matrix. Evading anoikis is a critical step in the process of metastasis
. Taken together, the finding that miR-221 could promote cell cycle progression and protect cells from apoptosis outlines the importance of the aberrant expression of one miRNA in cancer, whose action of on various targets could simultaneously affect multiple tumourigenic pathways. Signal pathways from activated RTKs include also the PI3K AKT. The activation of this pathway leads to the activation of AKT kinases, which phosphorylate several protein targets that in turn
New molecularly targeted agents with a selective action and few side effects on residual liver function are under investigation: taking advantage of the progresses in understanding the molecular pathogenesis of HCC, kinases inhibitors, anti-angiogenic
Concluding remarks
